Happy Thursday!
We hope everyone’s month is going well! This week, we’re highlighting two stories about drug pricing and reimbursement. Next, we have an article on mastocytosis diagnoses and (yet another) piece about rare disease on The Bachelor.
Sit back and enjoy this week’s Editor’s Choice.
[one_half]
[/one_half] [one_half_last]
Report Calls for Reducing Prices on Spinal Muscular Atrophy Drugs
The rare community has been watching approvals and criticisms of Spinraza– a very expensive SMA drug– play out over the last few years. A recent report says that the price should be reduced.
[/one_half_last]
[one_half]
[/one_half] [one_half_last]
Skyrocketing Drug Prices Prompt Discussion of New Reimbursement Schemes
Many people in the US can’t afford the medical care they need. This leads to the question– what are the alternative options?
[/one_half_last]
[one_half]
[/one_half] [one_half_last]
Accidental Discovery Gives Insight into New Potential Method of Diagnosis for Mastocytosis
Accidental discoveries are one of the wonderful things that propel medicine forward. This insight has impact for patients with mastocytosis.
[/one_half_last]
[one_half]
[/one_half] [one_half_last]
Why Does Rare Disease Keep Coming Up on The Bachelor?
As long as there’s a relationship between reality TV and rare disease, we’re going to write about it. Still, that leads to the big question: why are there so many mentions of rare disease on The Bachelor?
[/one_half_last]
[one_half]
